JY
XERS icon

Jeff Yass’s Xeris Biopharma Holdings XERS Stock Holding History

Jeff Yass’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1M Buy
265,200
+161,200
+155% +$1.03M ﹤0.01% 6377
2026
Q1 		$603K Sell
104,000
-186,900
-64% -$1.24M ﹤0.01% 9187
2025
Q4 		$2.28M Buy
290,900
+103,000
+55% +$811K ﹤0.01% 5365
2025
Q3 		$1.53M Buy
187,900
+142,800
+317% +$949K ﹤0.01% 6376
2025
Q2 		$211K Sell
45,100
-11,700
-21% -$53.6K ﹤0.01% 11107
2025
Q1 		$312K Buy
56,800
+35,600
+168% +$144K ﹤0.01% 9989
2024
Q4 		$71.9K Sell
21,200
-30,500
-59% -$98.1K ﹤0.01% 11525
2024
Q3 		$147K Buy
51,700
+13,900
+37% +$35.7K ﹤0.01% 10759
2024
Q2 		$85K Buy
37,800
+15,900
+73% +$32K ﹤0.01% 11125
2024
Q1 		$48.4K Sell
21,900
-107,400
-83% -$278K ﹤0.01% 11573
2023
Q4 		$304K Sell
129,300
-46,300
-26% -$85.5K ﹤0.01% 9814
2023
Q3 		$327K Buy
175,600
+8,200
+5% +$18.8K ﹤0.01% 9182
2023
Q2 		$439K Buy
167,400
+120,200
+255% +$306K ﹤0.01% 8607
2023
Q1 		$76.9K Sell
47,200
-230,400
-83% -$288K ﹤0.01% 11463
2022
Q4 		$369K Buy
277,600
+13,300
+5% +$18.8K ﹤0.01% 8608
2022
Q3 		$412K Sell
264,300
-181,700
-41% -$300K ﹤0.01% 8990
2022
Q2 		$687K Sell
446,000
-54,100
-11% -$114K ﹤0.01% 7467
2022
Q1 		$1.28M Buy
500,100
+426,900
+583% +$1.04M ﹤0.01% 6520
2021
Q4 		$214K Sell
73,200
-65,700
-47% -$142K ﹤0.01% 11307
2021
Q3 		$340K Sell
138,900
-156,000
-53% -$453K ﹤0.01% 10308
2021
Q2 		$1.2M Sell
294,900
-113,800
-28% -$434K ﹤0.01% 7252
2021
Q1 		$1.84M Buy
408,700
+42,300
+12% +$228K ﹤0.01% 6123
2020
Q4 		$1.8M Sell
366,400
-17,400
-5% -$87.1K ﹤0.01% 5304
2020
Q3 		$2.28M Buy
+383,800
New +$1.53M ﹤0.01% 4375

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jeff Yass's XERS Position: Q2 2026 in Review

Jeff Yass reduced its Xeris Biopharma Holdings (XERS) stake by 51% in Q2 2026, selling an estimated $933K and leaving 139,918 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #7934.

Jeff Yass first reported a position in XERS in Q2 2019 and has held it in 26 quarters since. The position peaked at $3.5M in Q1 2025. 237 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Jeff Yass held 139,918 shares of Xeris Biopharma Holdings worth $1.11M as of Q2 2026.
  • Jeff Yass sold 146,153 Xeris Biopharma Holdings shares in Q2 2026, an estimated $933K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7934 holding.
  • Jeff Yass first reported a position in Xeris Biopharma Holdings in Q2 2019 and has held it in 26 quarters since.
  • Jeff Yass's Xeris Biopharma Holdings position peaked at $3.5M in Q1 2025.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.